Semaglutide Oral Suspension — GLP-1 Oral Weight Loss | Newfield Health

Compounded medication notice: Semaglutide Oral Suspension is a compounded prescription medication. It is not FDA-approved and is not the same as Ozempic, Wegovy, or Rybelsus. A licensed provider determines whether this medication is appropriate after reviewing your health history.

Weight Loss · GLP-1 · Compounded Oral

GLP-1 appetite support
in an oral formulation

Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone signaling fullness. This compounded oral suspension offers a non-injectable option for qualified candidates.

Start your free intake →
Compounded — not FDA-approved No injection required Provider review required
GLP-1Receptor agonist
OralSuspension — no injection
WeeklyDosing schedule
Rx onlyProvider approval required
Why semaglutide

Addressing hunger at the hormonal level

Most weight loss approaches work at the level of behavior — asking you to eat less and resist hunger. Semaglutide works at a different level entirely. It mimics a hormone your gut naturally releases after eating — one that signals the brain the body is full and reduces appetite signaling.

The result, for appropriate candidates, is not a more heroic exercise of willpower. It is a meaningful reduction in how much hunger the body is generating in the first place. The food noise quiets. Feeling full comes sooner and stays longer.

This compounded oral suspension is not the same as Ozempic, Wegovy, or Rybelsus. It is a different formulation with different absorption characteristics. Your provider will discuss the evidence limitations of this specific preparation.

The distinction that matters
"Semaglutide doesn't ask you to override your hunger. It changes the signal — so the hunger is less there to override."
This is a compounded oral formulation. Clinical trial results from FDA-approved semaglutide products may not apply. Your provider will discuss what the evidence does and does not support.
How it works

What semaglutide does
in the body

Semaglutide activates GLP-1 receptors — the same receptors that respond to the gut hormone released naturally after eating.

Signals fullness to the brain
Activates GLP-1 receptors in the brain to produce stronger and longer-lasting fullness signals after eating.
Slows gastric emptying
Slows how quickly food moves from the stomach, extending the physical sensation of fullness after meals.
Reduces appetite signaling
Reduces baseline appetite — the between-meal hunger signals that drive snacking and caloric excess.
Supports blood sugar regulation
Stimulates insulin secretion and suppresses glucagon, supporting more stable blood sugar levels.

About this formulation: This is a compounded oral suspension with different absorption than FDA-approved injectable or oral tablet products. Your provider will discuss this during review.

Compare options

Other weight loss treatments

Not sure which option is right for you? Your physician will help determine the best fit based on your metabolic profile.

Metformin

Metabolic foundation · Oral tablet · FDA-approved

Learn more →

Semaglutide Oral Suspension

GLP-1 · Reduces appetite · Compounded oral

Current selection

Tirzepatide ODT

Dual GIP/GLP-1 · Compounded oral disintegrating tablet

Learn more →
What to expect

A realistic timeline

Weeks 1–8
Dose adjustment & appetite shift

GI side effects are most common during this window. Many patients notice the beginning of appetite quieting — feeling full sooner, less between-meal hunger.

Months 3–6
Appetite stabilization

GI side effects typically ease. Appetite reduction becomes more consistent. Weight effects follow appetite change.

Months 6–12+
Sustained results

Continued weight management at a stable dose alongside dietary and lifestyle habits. Your provider will discuss long-term protocol.

Note on absorption variability

Oral semaglutide formulations have inherently more variable absorption than injectable formulations. Individual response may vary more than with injectable GLP-1 medications.

Questions

What patients ask about
semaglutide oral suspension

Is this the same as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved injectable semaglutide products. This is a compounded oral suspension — not FDA-approved, not injectable, and not studied to the same standard.
Is this the same as Rybelsus?
No. Rybelsus is an FDA-approved oral semaglutide tablet. This compounded oral suspension is a different formulation with a different preparation approach.
Will I experience nausea?
Nausea is the most common side effect of GLP-1 medications and is most pronounced during dose titration. It typically improves as the body adjusts.
What if my provider prescribes metformin instead?
Your provider makes that determination based on your clinical profile. The program fee covers provider access regardless of which medication is prescribed.
Do I still need to change my diet?
Yes. GLP-1 medications reduce hunger — they do not eliminate the need for dietary changes. The mechanism works best when paired with intentional dietary adjustment.
What happens if I stop taking it?
Weight regain is common after stopping GLP-1 medications if dietary changes are not firmly established. Your provider will help you plan for long-term maintenance.

A GLP-1 pathway
without the injection

If you're looking for GLP-1 appetite support in an oral format and your provider determines this approach is clinically appropriate.

Start your free intake →

Important Safety Information

Compounded medication — not FDA-approved. Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN syndrome type 2. Common side effects: nausea, vomiting, diarrhea. GLP-1 medications are contraindicated during pregnancy. This information does not constitute medical advice. Provider review required.